summaryrefslogtreecommitdiffstats
diff options
context:
space:
mode:
authorDavid A. Madore <david+git@madore.org>2020-07-14 16:48:54 +0200
committerDavid A. Madore <david+git@madore.org>2020-07-14 16:48:54 +0200
commita0f4c77ac1ca4f2b675fb14856ae67879e1ffcc9 (patch)
treee5eaad811ab52feb1ee16be99a54e079b984dcdd
parent307b8a7da4f6446cc51df0f0edf0079134d2f9b6 (diff)
downloadcovid19-a0f4c77ac1ca4f2b675fb14856ae67879e1ffcc9.tar.gz
covid19-a0f4c77ac1ca4f2b675fb14856ae67879e1ffcc9.tar.bz2
covid19-a0f4c77ac1ca4f2b675fb14856ae67879e1ffcc9.zip
Add three papers on immunity.
-rw-r--r--covid19-links.md30
1 files changed, 30 insertions, 0 deletions
diff --git a/covid19-links.md b/covid19-links.md
index 4ad9f37..8168851 100644
--- a/covid19-links.md
+++ b/covid19-links.md
@@ -87,6 +87,36 @@
## Topical or time-specific links: ##
+* [Robust T cell immunity in convalescent individuals with
+ asymptomatic or mild
+ COVID-19](https://www.biorxiv.org/content/10.1101/2020.06.29.174888v1)
+ (2020-06-29 preprint). Key finding: “Our collective dataset shows
+ that SARS-CoV-2 elicits robust memory T cell responses akin to those
+ observed in the context of successful vaccines, suggesting that
+ natural exposure or infection may prevent recurrent episodes of
+ severe COVID-19 also in seronegative individuals.”
+
+* [Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune
+ Response without
+ Seroconversion](https://www.medrxiv.org/content/10.1101/2020.06.21.20132449v1)
+ (2020-06-20 preprint). Conclusion: “Exposure to SARS-CoV-2 can
+ induce virus-specific T cell responses without seroconversion. T
+ cell responses may be more sensitive indicators of SARS-Co-V-2
+ exposure than antibodies. Our results indicate that epidemiological
+ data relying only on the detection of SARS-CoV-2 antibodies may lead
+ to a substantial underestimation of prior exposure to the virus.”
+
+* [Systemic and mucosal antibody secretion specific to SARS-CoV-2
+ during mild versus severe
+ COVID-19](https://www.biorxiv.org/content/10.1101/2020.05.21.108308v1)
+ (2020-05-23 preprint). Main conclusion: “Data show that systemic
+ IgA and IgG production against SARS-CoV-2 develops mainly in severe
+ COVID-19, with very high IgA levels seen in patients with severe
+ ARDS, whereas mild disease may be associated with transient serum
+ titers of SARS-CoV-2-specific antibodies but stimulate mucosal
+ SARS-CoV-2-specific IgA secretion. The findings suggest four grades
+ of antibody responses dependent on COVID-19 severity.”
+
\[Note that around the end of May I stopped maintaining this list.
Still adding a few papers later, but it's definitely less complete
than it used to be.\]